BMT CTN Protocol 0301
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia
Below are protocol-related documents, which may be periodically updated.
- Protocol synopsis and schema, version 9.0 dated June 6, 2013
- Protocol, version 9.0 dated June 6, 2013
- Summary of changes from version 8.0 to version 9.0
- Informed consent, version 9.0 dated June 6, 2013
- Educational Materials
- Participating centers
- This study is posted on clinicaltrials.gov as NCT00326417
- Key Personnel
Protocol Chair: Paolo Anderlini, MD (713-794-5743) email@example.com
Protocol Officer: Mary Eapen, MD (414-805-0700) firstname.lastname@example.org
Protocol Coordinator: Iris Gersten, MS (301-251-1161) email@example.com
Medical Monitor: Chris Bredeson, MD firstname.lastname@example.org
This study reached target accrual and was closed to patient accruals on December 2, 2013.